Attending Physician, Hospital for Special Surgery
Professor of Clinical Medicine, Weill Cornell Medical College
Attending Physician, Department of Medicine, Memorial Sloan-Kettering Cancer Center
Crystalline Disease (Gout and pseudo gout)
Rheumatoid Arthritis (RA)
Systemic Lupus Erythematosus (SLE)
Blue Cross HMO POS
Blue Cross PPO
Blue Cross Pathway
Blue Cross Pathway Enhanced
Please do not hesitate to contact our office if you have questions regarding your insurance coverage. You may still have coverage subject to the availability of 'out-of-network' benefits.
One of the goals of Hospital for Special Surgery (HSS) is to advance the science of orthopedic surgery, rheumatology, and related disciplines for the benefit of patients. Physicians at HSS may collaborate with outside companies for education, research and medical advances. HSS supports this collaboration in order to foster medical breakthroughs; however HSS also believes that these collaborations must be disclosed.
As part of the disclosure process, this website lists physician collaborations with outside companies if payments were received during the prior year, or if the HSS physician currently receives payment. The disclosures are provided by information provided by the physician and other sources and are updated regularly. Further information may be available on individual company websites.
Below are the healthcare industry relationships reported by Dr. Markenson as of August 12, 2014.
The following firms organize Continuing Medical Education (CME) and promotional programs for which I receive honoraria as a Speaker: Advanced Health Media, AlphaBioCom, LLC, Apex Communications, Ethos, KnowledgePoint 360 Group, Medical Decisionpoint, LLC, Meetings & Events International, Miller Medical Communications, LLC, Steven H. Schafer & Associates, and WebMD.
By disclosing the collaborations of HSS physicians with industry on this website, HSS and its physicians make this information available to their patients and the public, thus creating a transparent environment for those who are interested in this information. Further, HSS’ Conflicts of Interest Policy does not permit physicians to collect royalties on products developed by him/her that are used on patients at HSS.
Patients should feel free to ask their HSS physicians questions about these relationships.
New York, New Jersey
Brostoff SW, Carlo DJ, Dively, et al: Results of a Phase II Rheumatoid Arthritis Clinical Trial Using T-Cell Receptor Peptides. In Advances in Osteoarthritis. Eds. S. Tanka, C. Hamanishi. Tokyo: Springer-Verlag, 1999, pp 153-162. .
Paget SA, Zuniga-Montes RL, Markenson JA and Bateman H. Heel Pain in the Setting of Metabolic, Infiltrative, and Bone Disorders. In Disorders of the Heel, Rearfoot and Ankle. Eds. C. Ranawat and R. Positano. Philadelphia, PA: Churchill Livingstone, 1999, pp 172-179.
Paget S.A., Bateman, H. Markenson, J.A., and Zuniga-Motes, L.R. Heel Pain and Achilles Pain Associated with Rheumatoid Arthritis and Seronegative Spondyloarthropathies. In Disorders of the Heel, Rearfoot, and Ankle. Eds. C. Ranawat and R. Positano Churchill Livingstone Philadelphia Pa. 1999 pp180-187
Markenson JA. Psoriatic Arthritis in Manual of Rheumatology and Outpatient Orthopedic Disorders. Eds. S.A. Paget, A. Gibofsky, and John F. Berry III. Philadelphia, PA: Lippincott, Williams & Wilkins, 2000, pg. 279.
Markenson J.A. Guest Editor Rheumatic Disease Clinic of North America. Rheumatologic Manifestations of Endocrine Disease. Elsevier Volume 36,4,2010
Markenson, J.A.,Using the new biologic therapies in rheumatoid arthritis: practical aspects. Future Rheumatol 2(5), 475-483,2007
Markenson, J.A. Rheumatic Manifestations of endocrine diseases: Curr Opin Rheum 22:64-71,2010
Gibofsky, A., W.R.Palmer, E.C.Keystone., et al Rheunmatoid Arthritis Disease-modifying Antirheumatic Drug Intervention and Utilization Study: Safety and Etanercept Utilization Analyses from the Radius 1 and Radius 2 Registries. J. Rheum. 2011 38(1) 21-28
Markenson, J.A.,A.G.Gibofsky,Palmer,W.R., et al Persistence with Anti-Tumor Necrosis Factor Therapies in Patients with Rheumatoid Arthritis: Observation from the RADIUS Registry. J.Rheum. 2011, 38(7) 1273-1281
Chakravarty,S.,D, and J.A.Markenson: Rheumatic Manifestations of Endocrine Disease: Curr Opin Rheum 2013,25:37-43
Markenson, J.A.,A.S.Koenig,Jing Yuan Feng, et al. Comparison of Physician and Patient Global Assessments Over Time in Patients With Rheumatoid Arthritis. A Retrospective Analysis From the RADIUS Cohort. JCR:2013, 19 (6): 314-323
Markenson, J.A. Commentary on Review: Glucosamine and chondroitin,alone or in combination,do not clinically improve knee or hip pain in osteoarthritis. ACP Journal Club 2011,154;(3) JC3-4
Markenson, J.A.,Charalambous,K.,Wiereck,C.,et al US Rheumatologists’ Attitudes,Practice Habits,Barriers, and Knowledge Gaps in Assessing and Monitoring Patients with Rheumatoid Arthritis according to Recent Recommendations. CE Measure. 2013:7:87-95
For more publications, please see the PubMed listing.
Dr. Joseph Markenson is the principal investigator for drug studies involving patients with Rheumatic Diseases (Rheumatoid Arthritis, Osteoarthritis and Lupus). Ongoing recruitment for enrollment in studies currently active. Patients interested in more information or to participate in a Clinical Drug Trial should call his office at 212.606.1261.
Clinical Trials on therapeutics for the rheumatic diseases